Firsocostat

DRUG3 trials

Sponsors

Gilead Sciences

Conditions

Nonalcoholic SteatohepatitisNonalcoholic Steatohepatitis (NASH)

Phase 1

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function

CompletedNCT02891408

Gilead SciencesNonalcoholic Steatohepatitis (NASH)

Start: 2016-09-23End: 2019-05-13Updated: 2020-12-17

Phase 2

Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

CompletedNCT02856555

Gilead SciencesNonalcoholic Steatohepatitis (NASH)

Start: 2016-08-08End: 2017-07-18Updated: 2020-07-24

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

CompletedNCT03987074

Gilead SciencesNonalcoholic Steatohepatitis

Start: 2019-07-29End: 2020-07-13Updated: 2021-07-15

Related Papers

NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials.

2025-01-019 citations

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.

2022-04-16155 citations

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.

2018-07-27255 citations

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.

2018-04-26167 citations